viewMaxCyte Inc

MaxCyte, Inc. - Notification of AGM and Audit Declaration

RNS Number : 0594P
MaxCyte, Inc.
08 October 2019




MaxCyte, Inc.

("MaxCyte" or the "Company")


Notification of Annual General Meeting and Declaration of Audit Remuneration


Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.


These documents are also available in electronic form on the Company's website: www.maxcyte.com.


In order to assist investors in considering the resolutions proposed ahead of the AGM, the Company notes that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for audit-related services relating to the 2018 financial year, amounted to approximately $99,200.


The Annual General Meeting of Stockholders is planned to be held at 11 a.m. EDT on 31 October 2019 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.



About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.







For further information, please contact:


MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer


+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns



+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith


+44 (0)20 7260 1000

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji




+44 (0)203 709 5700

[email protected]










This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: MaxCyte Inc

Price: 332

Market: AIM
Market Cap: £256.17 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18